Yazar "Yumru, Mehmet" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Lack of Association Between COMT Gene Polymorphism and Treatment Outcome in Major Depression
    (Yerkure Tanitim & Yayincilik Hizmetleri A S, 2011) Selek, Salih; Kaya, Mehmet C.; Erdal, Mehmet Emin; Bulut, Mahmut; Ozen, Murat Eren; Yumru, Mehmet; Barlas, Omer
    Background & Aim: Abnormal activity of Catechol-Omethyl transferase (COMT), as a major degrading enzyme of catecholaminergic neurotransmitters may be enrolled in the pathogenesis of mood disorders. The aim of this study was to investigate the association between COMT genetic polymorphism and major depression patients. Method: The study included 137 unrelated major depressive disorder (MDD) patients and 153 healthy unrelated controls, all were of Turkish origin. The patients were treated with antidepressant drugs for 8 weeks. All patients were assessed by Hamilton Depression Rating Scale (HDRS) before and after the antidepressant treatment. The analysis of COMT G1947A polymorphism was performed using PCR based endonuclease digestion method. Results: No significant difference was found between MDD and control subjects. In the MDD patients, there was no relationship between duration of illness, and pretreatment HDRS scores in respect to COMT gene polymorphism. The distribution of COMT genotypes and alleles was not significantly different among the controls and MDD patients. Conclusion: Our findings indicated that distribution of COMT genetic polymorphism were not different significantly between the patients and controls. No allele was found to be a predictor for treatment outcome by antidepressant therapy or for clinical manifestations in MDD.
  • [ X ]
    Öğe
    Serum resistin levels and metabolic changes in bipolar disorder
    (Yerkure Tanitim & Yayincilik Hizmetleri A S, 2012) Yumru, Mehmet; Gergerlioglu, H. Serdar; Savas, Haluk A.; Basarali, Kemal; Kalenderoglu, Aysun; Buyukbas, Sadik
    Aim: Metabolic changes in bipolar disorder appear to be among the cluster of disturbances that have insulin resistance as a common etiologic factor. Several recently discovered adipokines such as resistin and visfatin play a role in the pathogenesis of insulin resistance. In this study we aimed to evaluate the association between serum resistin levels and metabolic changes in bipolar disorder. Method: Sixty euthymic bipolar I disorder patients, of 29 on mood stabilizer (MS) (lithium, valproic acid, carbamazepine, and lamotrigine) treatment and of 31 on atypical antipsychotic (AA) (risperidone, quetiapine and olanzapine) treatment for at least 3 months, were enrolled. The control group consisted of 27 healthy members who have had similar distributions of age, sex, and BMI with the patients. Resistin, glucose, triglycerides, and high density lipoprotein (HDL) levels were measured in all groups. Results: Resistin levels were found to be significantly high in bipolar patients than that in the controls. However, when metabolic parameters were considered resistin levels were not significantly different between the patient and control groups (p>0.05). Conclusion: Despite serum resistin levels were high in bipolar patients, we did not find any association between metabolic disturbances and treatment modalities.